COX CARRIE SMITH
SEC CIK 1110753 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TXN | Texas Instruments | Dir | 46.5K | — | $5.60M | 9 | 2022-01-27 | 2026-05-13 |
| SOLV | Solventum | Dir | 16.4K | — | — | 3 | 2025-05-13 | 2026-04-30 |
| OGN | Organon & Co. | Executive COB, Dir | 77.9K | $602.2K | — | 2 | 2025-05-14 | 2025-11-12 |
| RNAC | Cartesian Therapeutics, Inc. | Dir | 15.6K | $200.2K | — | 4 | 2021-12-03 | 2025-01-02 |
| CAH | Cardinal Health | Dir | 41.6K | — | — | 2 | 2021-11-11 | 2022-11-09 |
Most active insiders at TXN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lizardi Rafael R | CFO, Sr. VP | — | $41.71M |
| 2 | Yunus Mohammad | Sr. VP | — | $13.82M |
| 3 | Gary Mark | Sr. VP | — | $9.06M |
| 4 | Roberts Mark T. | Sr. VP | — | $8.86M |
| 5 | Leonard Shanon J | Sr. VP | — | $6.52M |
| 6 | Ilan Haviv | COB, Pres, CEO, Dir | — | $5.61M |
| 7 | Ron Amichai | Sr. VP | — | $5.00M |
| 8 | BLINN MARK A | Dir | — | $4.86M |
| 9 | BAHAI AHMAD | Sr. VP | — | $4.70M |
| 10 | Craighead Martin S | Dir | — | $3.20M |
| 12 | COX CARRIE SMITH | Dir | — | $2.71M |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-14 18:49 | 2026-05-13 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | M - OptEx | $107.21 | +8,838 | 46.5K | +23% | +$947.5K |
| DM | 2026-05-14 18:49 | 2026-05-13 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | S - Sale+OE | $306.41 | -8,838 | 37.6K | -19% | -$2.71M |
| D | 2026-05-01 16:26 | 2026-04-30 | SOLV | Solventum | COX CARRIE SMITH | Dir | M - OptEx | $0.00 | +4,916 | 16.4K | +43% | $0 |
| D | 2026-03-30 | 2026-03-27 | SOLV | Solventum | COX CARRIE SMITH | Dir | M - OptEx | $0.00 | +6,336 | 11.5K | +123% | $0 |
| D | 2026-02-02 | 2026-01-29 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +525 | 37.6K | +1% | $0 |
| I | 2025-11-13 | 2025-11-12 | OGN | Organon & Co. | COX CARRIE SMITH | Executive COB, Dir | P - Purchase | $7.67 | +65.4K | 77.9K | +525% | +$501.6K |
| 2025-05-15 | 2025-05-14 | OGN | Organon & Co. | COX CARRIE SMITH | Dir | P - Purchase | $8.07 | +12.5K | 12.5K | New | +$100.6K | |
| D | 2025-05-15 | 2025-05-13 | SOLV | Solventum | COX CARRIE SMITH | Dir | M - OptEx | $0.00 | +5,148 | 5,148 | New | $0 |
| D | 2025-01-29 | 2025-01-27 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +614 | 37.1K | +2% | $0 |
| D | 2025-01-06 | 2025-01-02 | RNAC | Cartesian Therapeutics, Inc. | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +2,600 | 15.6K | +20% | $0 |
| D | 2024-01-29 | 2024-01-25 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +686 | 36.5K | +2% | $0 |
| D | 2024-01-04 | 2024-01-02 | RNAC | Cartesian Therapeutics, Inc. | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +178.0K | 390.9K | +84% | $0 |
| D | 2023-08-03 | 2023-07-31 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | S - Sale+OE | $180.04 | -16.1K | 35.8K | -31% | -$2.89M |
| DM | 2023-08-03 | 2023-07-31 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | M - OptEx | $62.88 | +16.1K | 45.8K | +54% | +$1.01M |
| D | 2023-01-30 | 2023-01-26 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +574 | 35.8K | +2% | $0 |
| 2022-11-10 | 2022-11-09 | CAH | Cardinal Health | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +2,308 | 41.6K | +6% | $0 | |
| 2022-06-15 | 2022-06-13 | RNAC | Cartesian Therapeutics, Inc. | COX CARRIE SMITH | Dir | P - Purchase | $1.15 | +130.0K | 212.9K | +157% | +$149.5K | |
| D | 2022-01-31 | 2022-01-27 | TXN | Texas Instruments | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +572 | 35.2K | +2% | $0 |
| 2021-12-06 | 2021-12-03 | RNAC | Cartesian Therapeutics, Inc. | COX CARRIE SMITH | Dir | P - Purchase | $2.95 | +17.2K | 82.9K | +26% | +$50.7K | |
| 2021-11-15 | 2021-11-11 | CAH | Cardinal Health | COX CARRIE SMITH | Dir | A - Grant | $0.00 | +3,709 | 39.3K | +10% | $0 |
Purchase Sale Sale after option exercise All abbreviations